A Case of Acalvaria in a Full Term, Live Born Male Infant

Crowder, Felistia N; Deskins, Seth J; Decker, Morgan; Parrish, Kylie

doi:10.7759/cureus.22430

Cited by 3 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our supposed diagnosis was first aplasia cutis congenital and secondly acalvaria or acrania. Crowder [7] noted these nosological and diagnostic difficulties. Thus the final diagnosis in his reported case was made after autopsy.…”

Section: Discussionmentioning

confidence: 99%

Bone Defect of the Cranial Vault: Difficulty of the Diagnostic about a Case, and Revew of Literature

Espérance¹,

Landry²,

Olivier³

et al. 2023

OJMN

View full text Add to dashboard Cite

The bone defects of the cranial vault encompassed rare malformations including acalvaria, hypocalvaria, acrania, hypocrania, anencephaly and exencephaly. They are also described in some pathological entities such as aplasia cutis congenita of the scalp. We report an unusual case of cephalic malformation which combine defects of the skin, the dura mater, and the bones of the vault, with a malformation of the central nervous system. This unique case emphasizes a problem of nosological definition between the terms mentioned above. acalvaria, the acrania, the hypocalvaria and the aplasia cutis congenita. Thus, herein, we proceed to a literature review of bone defects of the skull and their differential diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone Defect of the Cranial Vault: Difficulty of the Diagnostic about a Case, and Revew of Literature

Espérance¹,

Landry²,

Olivier³

et al. 2023

OJMN

View full text Add to dashboard Cite

show abstract

“…The differences have been remarked upon especially by embalmers (Crowder & O'Looney, 2022), but the abnormal characteristics of the fibrinous clots have also been noted by clinicians dealing with living patients (Dong & Corson, 2022;Thorp et al 2022). The strange new clotting structures have a greater coherence and insolubility than ordinary blood clots.…”

Section: International Journal Of Vaccine Theory Practice and Researc...mentioning

confidence: 98%

“…The abnormal clots are distinguished as well by the rapidity of their formation. Most importantly, their tangible toughness, and the consistency of their internal structure make them notably different from any ordinary blood clots (Crowder & O'Looney, 2022).…”

Section: International Journal Of Vaccine Theory Practice and Researc...mentioning

confidence: 99%

“…They have also been called "long haulers" (Rubin, 2022). However, the clinical outcomes in recipients of the experimental genetic therapies -for example, the BNT162b2 Pfizer product, as well as the other COVID-19 injectables -are well documented outside the mainstream medical publications in multiple reports by competent and independent observers (Crowder & O'Looney, 2022;Dong & Corson, 2022;McLernon, 2022;Trigoso, 2022). Also, independent researchers, as we document in this paper, have begun to link the abnormal clotting directly to the COVID-19 injectables, usually in recipients of two or more doses.…”

Section: Abnormal Clotting As a Hallmark Of The Sars-cov-2 Spike Proteinmentioning

confidence: 99%

“…There have been reports of extraordinary abnormal clots being removed from both living (Dong & Corson, 2022) and dead (Crowder & O'Looney, 2022;O'Looney et al, 2022;Trigoso, 2022) individuals who received one or more doses of a COVID-19 injectable, or some mix of more than one. By February 22, 2023 the in vivo experimental genetic therapy had already been administered in 13.29 billion doses -with 1,695,567 doses being added to the total in just one day in the still unfolding true narrative representation (see TNR-theory in Oller, 2014).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Abnormal Clots and All-Cause Mortality During the Pandemic Experiment: Five Doses of COVID-19 Vaccine Are Evidently Lethal to Nearly All Medicare Participants

Santiago¹,

Oller²

2023

Vaccine Theory Prac & Res

View full text Add to dashboard Cite

Nyström and Hammarström (2022) found 7 segments in the bio-active SARS-CoV-2 spike protein that can produce abnormal proteinaceous (fibrinaloid) clots according to the Waltz algorithm. In vitro results confirmed the Waltz predictions. If the spike coding sequence was captured in the BNT162b2, Moderna, and other injectables, as claimed by the manufacturers, the clot producing segments are present in them too. Mainstream medical publications claim that SARS-CoV-2 infection can cause abnormal clotting, especially in “long COVID”. Telling evidence from Medicare data shows a decreasing life expectancy with each dose of COVID-19 “vaccine” — 1 dose is worse than 0, and 2 worse than 1, etc. In Connecticut, 26,091 Medicare participants who died before December 31, 2022, but never took a COVID injection, on the average, survived 428 days after the middle of the pandemic period (July 27, 2020). By then nearly all of them must have been exposed to and/or infected by some SARS-CoV-2 variant — hence, the CDC urging to take the “vaccines”. By contrast, 108,156 Medicare patients across the US who died before January 1, 2023, after just 1 dose of COVID-19 “vaccine”, survived only 308 days — a loss of 119.9 days on the average. Connecticut participants, 23,248 of them, who received 2 to 5 doses, on the average, lost an additional 62 days of life-expectancy with each booster. It follows that 5 boosters times 62 days reduces the average remaining 308 days left-to-live after dose 1 by 310 days. So, nearly all the Medicare participants will have been dead for 2 days by booster 4 (dose 5). The upshot is that 5 doses, on the average, will kill all the Medicare participants who accept the advice of the CDC.[1] For 157,495 of the 65 and older Medicare population studied here — people supposedly most apt to benefit from COVID-19 injectables — days-left-to-live shrinks by 74 days, on the average, with each dose. It is also likely that the COVID-19 injectables are partly, maybe wholly, responsible for the unnatural clots found by treating physicians, pathologists, and embalmers in living and dead recipients of the experimental injectables. It is certain is that the injectables are increasing all-cause mortality across the globe. [1] In the dataset from Connecticut, only 7 of 57,261 Medicare participants (7/57261 = 0.000122), or about 1.22 persons in 10,000 survived 5 doses during the experimental pandemic in order to take a 6th dose. Those who did so died, on the average, in 34 days. Only 1 participant survived 6 doses to receive a 7th and died within 69 days at the age of 68.

show abstract